BNET Industries

Market Cap:$140.6B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Pfizer says cuts may help research
-
Status Of Pfizer And Wyeth Research Facilities
-
Monsanto MON Agrees to Acquire Pfizer's PFE Chesterfield Village Research Center for $435M
-
Pfizer slashing 600 jobs from its St. Louis area work force [St. Louis Post-Dispatch]
-
UPDATE: Abbott Labs: US Justice Department Probing Depakote
-
Trubion loses $6.2 million in Q3
-
BRIEF: Pfizer, Ligand ink JAK-3 pact
-
Generics Makers Line Up To Sell Copies Of Pfizer's Lipitor
-
ViiV Healthcare launches: A new specialist HIV company dedicated to delivering advances in HIV treatment...
-
xtremepicks.com: www.Xtremepicks.Com: Xtremepicks Alerts November 4, 2009 : FLML, XING, AFFY and MOCO
-
Pfizer unveils its new Poultry Health division
-
Pfizer reportedly considers buying Protalix
-
Pfizer, GSK launch HIV drug company
-
Pfizer eyes deal with Israel's Protalix-newspaper
-
Report: Pfizer may make a bid for Protalix
-
Wockhardt says no plans to divest biotech biz
-
Pfizer Is Ordered to Pay $850,000 to Brigham Young U. for Delaying Patent Litigation
-
Pfizer leaders get $2.2 million in bonuses
-
AstraZeneca Settles Seroquel Probe
News & Analysis
Filter by
pfizer inc. and pharmaceutical company - All News and Analysis
Flu Windfalls Boost Big Pharma
By Ben HirschlerLONDON (Reuters UK) - It is turning out to be a better year for Big Pharma than initially feared, thanks to hefty drug price increases and windfall sales from swine flu.What's more, the industry dodged a bullet over the summer on U.S. healthcare reform, leaving company executives relatively...
The 10 Weirdest Drug Stories of the Month
April 2009 has come and gone, and once again it is time for BNET's roundup of the top 10 weirdest drug stories of the month. Enjoy! Bayer has a flock of sheep mow its lawn About 1450 sheep grazed Bayer's Richmond, Calif., campus last nonth, eating...
Pfizer, Vertex Execs Are Victims of Facebook Faker; Forbes, WSJ Also Targeted
Someone is impersonating prominent members of the pharma and biotech world on Facebook, including Vertex Pharmaceuticals chief executive Joshua Boger, a chief science officer at Pfizer and Forbes drug writer Matt Herper. by Jim Edwards
Claim: LeCarre's "The Constant Gardener" Was Based on Pfizer Trovan Case
The Connecticut Law Tribune claims that The Constant Gardener, a John Le Carré book and later a movie with the same name, is in fact based on the Pfizer Trovan case. But is the claim true? A look at the timeline of both the case and the book suggest it...
Waters Corp. Q4 FY08 Earnings Call
Question-and-Answer SessionOperator [Operator Instruction] Your first question comes from Ross Muken, Deutsche Bank. Your line is open. Ross Muken - Deutsche Bank Good morning, gentlemen. Douglas Berthiaume Good morning Ross. Ross Muken - Deutsche Bank Can you walk us through on the instrument side, sort...
Pharma Roundup: Lilly's Zyprexa Settlement; Cuts at Pfizer, Roche; and More
Lilly's Zyprexa settlment is biggest ever; Pfizer may cut 2,400; Roche cuts 780; Novartis' Ebeling on the future of pharma. by John Maas
Pharma Roundup: Pfizer's Acquisition Plans, Prasugrel's Big Day, and More
Pfizer wants acquisitions, big and small. Prasugrel has a date with the FDA. New Year's blog feature bonanza. Farewell, Pharmalot. by John Maas
Starved of News, Press Speculates on Deals for Abbott, Pfizer and Wyeth
New Year is a slow news period, which is why the business press filled up with next-to-useless corporate strategy stories about Abbott Labs, Wyeth and Pfizer. The one thing these stories all have in common? They're long on speculation and short on substance. Let's take them one at a time....
Pharma Roundup: AstraZeneca and Teva Mend Fences, Barbara Ryan's M&A Speculation, and More
AstraZeneca and Teva settle a potentially-acrimonious patent battle. Barbara Ryan speculates on pharma M&A. EU criticizes "strategic patenting." Indonesia wants drug production facilities from Big Pharma. by John Maas
Pharma Roundup: Amylin Cuts Jobs, Sanofi Faces Hard Times, and More
Amylin cuts 340 jobs, UBS predicts hard times for Sanofi, Pfizer sells a factory and GSK will close one. by John Maas
Industry Transcripts by Seeking Alpha
-
Alexza Pharmaceuticals, Inc., Q3 2009 Earnings Call Transcript
on Nov 09, 2009about ALXA
-
Salix Pharmaceuticals Ltd Q3 2009 Earnings Call Transcript
on Nov 09, 2009about SLXP
-
ACADIA Pharmaceuticals, Inc. Q3 2009 Earnings Conference Call
on Nov 09, 2009about ACAD
-
XOMA Ltd. Q3 2009 Earnings Call Transcript
on Nov 09, 2009about XOMA
-
Halozyme Therapeutics, Inc. Q3 2009 Earnings Call Transcript
on Nov 06, 2009about HALO
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
